The identification of the splicing aberrations induced by SF3B1 mutation in the HSCs of MDS patients will shed light on the downstream effects that lead to the MDS phenotype and may allow for the identification of new therapeutic targets in this disease. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.